References and Notes
-
1a
Kleeman A.
Engel J.
Kutscher B.
Reichert D.
Pharmaceutical
Substances, Synthesis, Patents, Applications
Thieme;
Stuttgart,
New York:
2001.
-
1b
Michael JP.
Nat. Prod. Rep.
2001,
18:
543
-
1c
Funayama S.
Murata K.
Noshita T.
Heterocycles
2001,
54:
1139
- 2
Huang LJ.
Hsieh MC.
Teng CM.
Lee KH.
Kuo
SC.
Bioorg. Med. Chem.
1998,
6:
1657
- 3
Musser JH.
Chakraborty UR.
Sciortino S.
Gordon RJ.
Khandwala A.
Neiss ES.
Pruss TP.
Van Inwegen R.
Weinryb I.
Coutts SM.
J. Med. Chem.
1987,
30:
96
- 4
Gauthier JY.
Jones T.
Champion E.
Charette L.
Dehaven R.
Ford-Hutchinson AW.
Hoogsteen K.
Lord A.
Masson P.
Piechuta H.
Pong SS.
Springer JP.
Therien M.
Zamboni R.
Young RN.
J.
Med. Chem.
1990,
33:
2841
-
For example:
-
5a
Majumder S.
Gipson KR.
Odom AL.
Org.
Lett.
2009,
11:
4720
-
5b
Martinez R.
Ramon DJ.
Yus M.
J.
Org. Chem.
2008,
73:
9778
-
5c
Schramm OG.
Oeser T.
Kaiser M.
Brun R.
Müller TJJ.
Synlett
2008,
359
-
5d
Zhang ZH.
Tan JJ.
Wang ZY.
Org. Lett.
2008,
10:
173
-
5e
Horn J.
Marsden SP.
Nelson A.
House D.
Weingarten GG.
Org.
Lett.
2008,
10:
4117
-
5f
Li L.
Jones WD.
J. Am. Chem. Soc.
2007,
129:
10707
-
5g
Sandelier MJ.
DeShong P.
Org. Lett.
2007,
9:
3209
- 6
Li H.
Zheng C.
Chen RE.
Su WK.
Org. Prep. Proced. Int.
2009,
41:
156
-
7a
Wolf C.
Lerebours R.
J.
Org. Chem.
2003,
68:
7077
-
7b
Pierce AC.
ter Haar E.
Binch HM.
Kay DP.
Patel SR.
Li P.
J.
Med. Chem.
2005,
48:
1278
-
7c
Andersen KE.
Lundt BF.
Jorgensen AS.
Braestrup C.
Eur.
J. Med. Chem.
1996,
31:
417
-
7d
Holla BS.
Mahalinga M.
Karthikeyan MS.
Poojary B.
Akberali PM.
Kumari NS.
Eur.
J. Med. Chem.
2005,
40:
1173
-
7e
Zhong BY.
Al-Awar RS.
Shih C.
Grimes
JH.
Vieth M.
Hamdouchi C.
Tetrahedron
Lett.
2006,
47:
2161
-
7f
Lim J.
Stock N.
Pracitto R.
Boueres JK.
Munoz B.
Chaudhary A.
Santini AM.
Orr K.
Schaffhauser H.
Bezverkov RE.
Aiyar J.
Venkatraman S.
Bioorg. Med. Chem. Lett.
2004,
14:
1913
- 8
Sashida H.
Fujii A.
Tsuchiya T.
Chem.
Pharm. Bull.
1987,
35:
3182
- 9
Smith KM.
Miura M.
Tabba HD.
J.
Org. Chem.
1983,
48:
4779
- 10
Kumar KH.
Peruma PT.
J. Heterocycl. Chem.
2008,
45:
597
- 11
Delfourne E.
Darro F.
Bontemps-Subielos N.
Decaestecker C.
Bastide J.
Frydman A.
Kiss R.
J.
Med. Chem.
2001,
44:
3275
- 12
Ismail MM.
Abass M.
Hassan MM.
Molecules
2000,
5:
1224
-
14a
Brahma S.
Ray JK.
J.
Heterocycl. Chem.
2008,
45:
311
-
14b
Brahma S.
Ray JK.
Tetrahedron Lett.
2005,
46:
6575
-
14c
Becher J.
Jorgensen PL.
Pluta K.
Krake NJ.
Falt-Hansen B.
J.
Org. Chem.
1991,
57:
2127
13
Experimental Procedure
for the Synthesis of 4-Chloro-2-substituted Quinolines; 1,3-(2
H
)-dicarbaldehyde
1o-r: To an ice-cold magnetically stirred solution
of DMF (10 mL) and 2-arylquinoline (5.0 mmol), POCl3 (30
mmol, 2.8 mL) was added dropwise. The reaction mixture was heated
to
50 ˚C for 3 h. After which it was poured into
the crush ice, neutralized with sat. K2CO3 solution
and extracted with EtOAc. After drying and condensation of the organic
layer , the crude reaction product was purified by column chromatography
using 5% EtOAc in PE as eluent to afford pure 1o-r.
15
General Procedure
for the Synthesis of 2-Substituted Quinolines 2a-n:
To a solution of DMSO (5 mL) and 4-chloro-N-formyl-1,2-dihydroquinolines 1a-n (1.0
mmol), NaN3 (1 mmol, 0.065 g) was added at r.t. The solution
was then heated at the indicated temperature (90 ˚C or
120 ˚C or 150 ˚C) for the indicated time. After
completion of the reaction (monitored by TLC) the mixture was treated
with ice-water and extracted with EtOAc. The organic layer was washed
with H2O, and then with brine. After condensation of the
organic layer, the products 2a-n were obtained by column chromatography
(PE-EtOAc).
2-(2-Chloro-6-fluorophenyl)quinoline
(2f)
New compound. Yield: 99%; light yellow
oil; R
f
0.53 (PE-EtOAc,
5:1). ¹H NMR (400 MHz, CDCl3): δ = 8.27
(1 H, d, J = 8.0 Hz), 8.20 (1
H, d, J = 8.4 Hz), 7.89 (1 H,
d, J = 8.0 Hz), 7.74-7.79
(1 H, m), 7.60 (1 H, t, J = 8.0
Hz), 7.50 (1 H, d, J = 8.0 Hz),
7.32-7.38 (2 H, m), 7.11-7.16 (1 H, m). ¹³C NMR
(100 MHz, CDCl3): δ = 160.7 (d, ¹
J
C-F = 248.7
Hz), 152.5, 147.9, 136.4, 134.3, 130.2 (d, ³
J
C-F = 9.9
Hz), 129.8, 129.6, 127.6, 127.3, 127.1, 125.6 (d, 4
J
C-F = 3.1
Hz), 123.0, 114.6 (d, ²
J
C-F = 22.0
Hz). HRMS (ESI): m/z [M + H]+ calcd for
C15H10ClFN: 258.0408; found: 258.0477.
16
General Procedure
for the Synthesis of 4-Substituted Isoxazolo[4,3-
c
]quinolines-5-(4
H
)-carbaldehyde
3o-r: To a solution of DMSO
(5 mL) and 4-chloro-2-substituted quinolines-1,3 (2H)-dicarbaldehyde 1o-r (1.0
mmol), NaN3 (1.5 mmol, 0.098 g) was added at r.t. and
the reaction mixture was kept at this temperature for 0.5 h. After completion
of the reaction (monitored by TLC) the mixture was treated with
ice-water and extracted with EtOAc. The organic layer was washed
with H2O, and then with brine. After condensation of
the organic layer, the products 3o-r were obtained by column chromatography
(PE-EtOAc).
4-Phenylisoxazolo[4,3-
c
]quinoline-5-(4
H
)-carbaldehyde
(3o)
New compound. Yield: 88%; white crystals;
mp 176-178 ˚C; R
f
0.46
(PE-EtOAc, 3:1). IR (KBr): 3121, 3057, 2851, 1677, 1609,
1574, 1475 cm-¹. ¹H
NMR (400 MHz, DMSO): δ = 9.21 (1 H, s), 8.86 (1
H, s), 7.94 (1 H, d, J = 8.0
Hz), 7.73 (1 H, d, J = 8.0 Hz),
7.54-7.59 (1 H, m), 7.37-7.41 (1 H, m), 7.22-7.30
(3 H, m), 7.16 (2 H, d, J = 8.0
Hz), 7.10 (1 H, s). ¹³C NMR (100 MHz,
DMSO): δ = 162.4, 156.0, 153.8, 138.8, 136.1,
132.2, 128.7, 127.8, 126.3, 126.1, 124.6, 121.2, 117.1, 114.7, 46.9.
HRMS (EI): m/z [M+] calcd
for C17H12N2O2: 276.0899;
found: 276.0899.